Latham & Watkins has advised a club of direct lenders in relation to the approximately €700 million financing in connection with the co-investment of Ardian and NB Renaissance in Neopharmed Gentili S.p.A., a leading pharmaceutical company operating in the Italian market.

Latham previously advised the lenders on Ardian’s initial investment in Neopharmed Gentili in November 2018.

The Latham team was led by Milan partners Marcello Bragliani, Antongiulio Scialpi, and Jeff Lawlis, and London partner Fergus O’Domhnaill; with Milan associates Davide Camasi and Pasquale Spiezio; London associates Julie Van der Meersche, Chloe Gontier, and Philip Rigley; and Madrid associate Blanca Vazquez de Castro.